Viromimetic STING Agonist-Loaded Hollow Polymeric Nanoparticles for Safe and Effective Vaccination against Middle East Respiratory Syndrome Coronavirus.
Middle East respiratory syndrome coronavirus
STING
cdGMP adjuvant
hollow nanoparticle
virus mimicry
Journal
Advanced functional materials
ISSN: 1616-301X
Titre abrégé: Adv Funct Mater
Pays: Germany
ID NLM: 101190390
Informations de publication
Date de publication:
11 Jul 2019
11 Jul 2019
Historique:
received:
29
10
2018
revised:
17
03
2019
entrez:
22
4
2020
pubmed:
22
4
2020
medline:
22
4
2020
Statut:
ppublish
Résumé
The continued threat of emerging, highly lethal infectious pathogens such as Middle East respiratory syndrome coronavirus (MERS-CoV) calls for the development of novel vaccine technology that offers safe and effective prophylactic measures. Here, a novel nanoparticle vaccine is developed to deliver subunit viral antigens and STING agonists in a virus-like fashion. STING agonists are first encapsulated into capsid-like hollow polymeric nanoparticles, which show multiple favorable attributes, including a pH-responsive release profile, prominent local immune activation, and reduced systemic reactogenicity. Upon subsequent antigen conjugation, the nanoparticles carry morphological semblance to native virions and facilitate codelivery of antigens and STING agonists to draining lymph nodes and immune cells for immune potentiation. Nanoparticle vaccine effectiveness is supported by the elicitation of potent neutralization antibody and antigen-specific T cell responses in mice immunized with a MERS-CoV nanoparticle vaccine candidate. Using a MERS-CoV-permissive transgenic mouse model, it is shown that mice immunized with this nanoparticle-based MERS-CoV vaccine are protected against a lethal challenge of MERS-CoV without triggering undesirable eosinophilic immunopathology. Together, the biocompatible hollow nanoparticle described herein provides an excellent strategy for delivering both subunit vaccine candidates and novel adjuvants, enabling accelerated development of effective and safe vaccines against emerging viral pathogens.
Identifiants
pubmed: 32313544
doi: 10.1002/adfm.201807616
pii: ADFM201807616
pmc: PMC7161765
doi:
Types de publication
Journal Article
Langues
eng
Pagination
1807616Informations de copyright
© 2019 WILEY‐VCH Verlag GmbH & Co. KGaA, Weinheim.
Déclaration de conflit d'intérêts
The authors declare no conflict of interest.
Références
Nanotheranostics. 2017 Jun 9;1(3):244-260
pubmed: 29071191
J Immunol. 2002 Jul 1;169(1):359-65
pubmed: 12077265
J Immunol. 2017 Dec 1;199(11):3840-3848
pubmed: 29084836
Vaccine. 2014 Oct 14;32(45):5975-82
pubmed: 25192975
Immunol Res. 2014 Aug;59(1-3):118-28
pubmed: 24845462
Vaccine. 2018 Apr 12;36(16):2069-2078
pubmed: 29550192
Adv Funct Mater. 2019 Jul 11;29(28):1807616
pubmed: 32313544
Nature. 2007 Nov 1;450(7166):110-4
pubmed: 17934446
Cell Host Microbe. 2016 Jun 8;19(6):760-9
pubmed: 27281568
Sci Immunol. 2017 Nov 10;2(17):
pubmed: 29127106
Vaccine. 2014 Apr 11;32(18):2100-8
pubmed: 24560617
Proc Natl Acad Sci U S A. 2015 Jan 13;112(2):488-93
pubmed: 25548169
PLoS One. 2013 Dec 04;8(12):e81587
pubmed: 24324708
Bio Protoc. 2013;3(14):
pubmed: 25429368
J Vis Exp. 2008 Jul 09;(17):
pubmed: 19066518
J Virol. 2013 Nov;87(21):11950-4
pubmed: 23986586
J Virol. 2015 Apr;89(7):3659-70
pubmed: 25589660
Vaccine. 2018 Mar 27;36(14):1853-1862
pubmed: 29496347
J Control Release. 2018 Jan 28;270:1-13
pubmed: 29170142
Vaccine. 2017 Jun 27;35(30):3780-3788
pubmed: 28579232
Nanomedicine (Lond). 2014 Dec;9(17):2639-56
pubmed: 25529568
Sci Immunol. 2017 Aug 4;2(14):
pubmed: 28778905
N Engl J Med. 2012 Nov 8;367(19):1814-20
pubmed: 23075143
J Virol. 2015 Oct 07;90(1):57-67
pubmed: 26446606
Nat Commun. 2015 Jul 28;6:7712
pubmed: 26218507
J Virol. 2011 Dec;85(23):12201-15
pubmed: 21937658
Cell Rep. 2018 Dec 11;25(11):3074-3085.e5
pubmed: 30540940
Science. 1999 May 14;284(5417):1143-6
pubmed: 10325219
Nanomedicine. 2018 Feb;14(2):237-246
pubmed: 29127039
Cell Mol Immunol. 2016 Mar;13(2):180-90
pubmed: 25640653
Immunology. 2015 Aug;145(4):476-84
pubmed: 25762305
J Virol. 2015 Mar;89(6):2995-3007
pubmed: 25520500
Cell Rep. 2016 Dec 6;17(10):2503-2511
pubmed: 27926855
Immunity. 2016 Jun 21;44(6):1379-91
pubmed: 27287409
Nat Biotechnol. 2015 Nov;33(11):1201-10
pubmed: 26501954
Nat Rev Immunol. 2012 Nov;12(11):749-61
pubmed: 23080391
J Immunol. 2015 Mar 15;194(6):2455-65
pubmed: 25747907
Nat Commun. 2018 Aug 1;9(1):3005
pubmed: 30068976
Nat Mater. 2013 Nov;12(11):978-90
pubmed: 24150416
Nat Biotechnol. 2007 Oct;25(10):1159-64
pubmed: 17873867
J Virol. 2015 Aug;89(16):8651-6
pubmed: 26018172
Nature. 2006 Apr 6;440(7085):808-12
pubmed: 16489357
Antimicrob Agents Chemother. 2015 Feb;59(2):1273-81
pubmed: 25512416
Proc Natl Acad Sci U S A. 2018 Aug 14;115(33):E7758-E7767
pubmed: 30065113
Proc Natl Acad Sci U S A. 2016 Jul 19;113(29):8098-103
pubmed: 27382168
J Virol. 2004 Nov;78(22):12672-6
pubmed: 15507655
Hum Vaccin Immunother. 2015;11(5):1244-50
pubmed: 25874632
Int Immunol. 2008 Dec;20(12):1551-63
pubmed: 18931363
Vaccine. 2014 May 30;32(26):3169-3174
pubmed: 24736006
Proc Natl Acad Sci U S A. 2014 Apr 1;111(13):4970-5
pubmed: 24599590
Nature. 2009 Oct 8;461(7265):788-92
pubmed: 19776740
Science. 2013 Feb 15;339(6121):786-91
pubmed: 23258413
Vaccine. 2014 Oct 21;32(46):6170-6176
pubmed: 25240756
Antiviral Res. 2017 Jan;137:82-92
pubmed: 27840203
Nat Rev Immunol. 2015 Apr;15(4):231-42
pubmed: 25790790
Vaccine. 2014 May 30;32(26):3216-22
pubmed: 24731807
Science. 2013 Feb 15;339(6121):826-30
pubmed: 23258412
PLoS One. 2014 Nov 18;9(11):e112602
pubmed: 25405618
PLoS One. 2012;7(4):e35421
pubmed: 22536382
Hum Vaccin Immunother. 2016 Sep;12(9):2351-6
pubmed: 27269431
J Control Release. 2015 Mar 10;201:22-31
pubmed: 25540904
EBioMedicine. 2015 Aug 18;2(10):1438-46
pubmed: 26629538
Infect Immun. 2008 Jun;76(6):2392-401
pubmed: 18362126
Sci Transl Med. 2012 Apr 4;4(128):128ra39
pubmed: 22491949
Nanomedicine. 2013 May;9(4):523-31
pubmed: 23178283
J Microbiol Methods. 2010 Jun;81(3):226-31
pubmed: 20385176
Nat Immunol. 2002 Mar;3(3):265-71
pubmed: 11828323
Vaccine. 2017 Mar 14;35(12):1586-1589
pubmed: 28237499
Sci Transl Med. 2015 Aug 19;7(301):301ra132
pubmed: 26290414
Adv Biosyst. 2017 Feb;1(1-2):
pubmed: 30258983
Nat Immunol. 2010 May;11(5):427-34
pubmed: 20305659
Vaccine. 2017 May 2;35(19):2550-2557
pubmed: 28385609
Mol Pharm. 2013 Jan 7;10(1):319-28
pubmed: 23259920
PLoS Pathog. 2017 Aug 17;13(8):e1006565
pubmed: 28817732
Sci Immunol. 2016 Oct 21;1(4):
pubmed: 27872905
J Clin Invest. 2015 Jun;125(6):2532-46
pubmed: 25938786
Vaccine. 2014 May 19;32(24):2882-95
pubmed: 24593999
Science. 2013 Sep 20;341(6152):1390-4
pubmed: 23989956
Science. 2016 Jan 1;351(6268):77-81
pubmed: 26678878
J Exp Med. 2018 May 7;215(5):1273-1285
pubmed: 29666166
J Exp Med. 2003 Aug 4;198(3):399-410
pubmed: 12885871
JCI Insight. 2018 May 17;3(10):
pubmed: 29769448
Nature. 2011 Sep 25;478(7370):515-8
pubmed: 21947006
Mol Pharm. 2018 Nov 5;15(11):4933-4946
pubmed: 30281314
J Immunol. 2017 Jan 15;198(2):873-882
pubmed: 27903740
Vaccines (Basel). 2015 Oct 16;3(4):850-74
pubmed: 26501327